Myelodysplastic syndromes

Common Name(s)

Myelodysplastic syndromes, MYELODYSPLASTIC SYNDROME

Myelodysplastic syndromes (MDS) are a rare group of blood disorders characterized by abnormal development of blood cells within the bone marrow. Individuals with MDS have abnormally low blood cell levels (low blood counts). Signs and symptoms associated with MDS include dizziness, fatigue, weakness, shortness of breath, bruising and bleeding, frequent infections, and headaches. In some cases, MDS may progress to bone marrow failure or an acute leukemia. The exact cause of MDS is unknown. It sometimes runs in families, but no disease-causing gene has been identified. Treatment depends on the affected individual's age, general health, and type of MDS and may include red cell and/or platelet transfusions and antibiotics.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Myelodysplastic syndromes" for support, advocacy or research.

Logo
Aplastic Anemia & MDS International Foundation

The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH), and related bone marrow failure diseases. AA&MDSIF provides answers, support and hope to thousands of patients and their families around the world.

Last Updated: 29 Apr 2014

View Details
National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Myelodysplastic syndromes" for support, advocacy or research.

Logo
Aplastic Anemia & MDS International Foundation

The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH), and related bone marrow failure diseases. AA&MDSIF provides answers, support and hope to thousands of patients and their families around the world.

http://www.aamds.org/

Last Updated: 29 Apr 2014

View Details
National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

http://www.nbmtlink.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Myelodysplastic syndromes" returned 693 free, full-text research articles on human participants. First 3 results:

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
 

Author(s): John S Welch, Allegra A Petti, Christopher A Miller, Catrina C Fronick, Michelle O'Laughlin, Robert S Fulton, Richard K Wilson, Jack D Baty, Eric J Duncavage, Bevan Tandon, Yi-Shan Lee, Lukas D Wartman, Geoffrey L Uy, Armin Ghobadi, Michael H Tomasson, Iskra Pusic, Rizwan Romee, Todd A Fehniger, Keith E Stockerl-Goldstein, Ravi Vij, Stephen T Oh, Camille N Abboud, Amanda F Cashen, Mark A Schroeder, Meagan A Jacoby, Sharon E Heath, Kierstin Luber, Megan R Janke, Andrew Hantel, Niloufer Khan, Madina J Sukhanova, Randall W Knoebel, Wendy Stock, Timothy A Graubert, Matthew J Walter, Peter Westervelt, Daniel C Link, John F DiPersio, Timothy J Ley

Journal: N. Engl. J. Med.. 2016 Nov;375(21):2023-2036.

 

Background The molecular determinants of clinical responses to decitabine therapy in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are unclear. Methods We enrolled 84 adult patients with AML or MDS in a single-institution trial of decitabine to identify ...

Last Updated: 13 Dec 2016

Go To URL
Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT.
 

Author(s): E M P Cremers, A van Biezen, L C de Wreede, M Scholten, A Vitek, J Finke, U Platzbecker, D Beelen, R Schwerdtfeger, L Volin, N Harhalakis, N Blijlevens, A Nagler, N Kröger, T de Witte

Journal: Ann. Hematol.. 2016 Dec;95(12):1971-1978.

 

Many pre-transplant factors are known to influence the outcome of allogeneic stem cell transplantation (SCT) treatment in myelodysplastic syndromes (MDS). However, patient cohorts are often heterogeneous by disease stage and treatment modalities, which complicates interpretation of ...

Last Updated: 21 Sep 2016

Go To URL
Clinical features and prognosis of patients with myelodysplastic syndromes who were exposed to atomic bomb radiation in Nagasaki.
 

Author(s): Masatoshi Matsuo, Masako Iwanaga, Hisayoshi Kondo, Midori Soda, Tatsuro Jo, Kensuke Horio, Yumi Takasaki, Yasuhisa Kawaguchi, Hideki Tsushima, Yoshitaka Imaizumi, Daisuke Imanishi, Jun Taguchi, Yasushi Sawayama, Tomoko Hata, Yasushi Miyazaki

Journal: Cancer Sci.. 2016 Oct;107(10):1484-1491.

 

There is evidence that radiation exposure is a causative factor of myelodysplastic syndromes (MDS). However, little is known about whether radiation exposure is also a prognostic factor of MDS. We investigated the impact of radiation exposure on the prognosis of MDS in Nagasaki atomic ...

Last Updated: 2 Sep 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Myelodysplastic syndromes" returned 140 free, full-text review articles on human participants. First 3 results:

Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes.
 

Author(s): Rami S Komrokji

Journal: Am Soc Clin Oncol Educ Book. 2016 ;35():e345-52.

 

Hypomethylating agents (HMAs) are the mainstay treatment of patients with myelodysplastic syndromes. Hypomethylating agents remain the only treatment, other than allogeneic hematopoietic stem cell transplantation (AHSCT), that improves overall survival (OS) for patients with higher-risk ...

Last Updated: 2 Jun 2016

Go To URL
Integrating Frailty, Comorbidity, and Quality of Life in the Management of Myelodysplastic Syndromes.
 

Author(s): Gregory A Abel, Rena Buckstein

Journal: Am Soc Clin Oncol Educ Book. 2016 ;35():e337-44.

 

Myelodysplastic syndromes (MDS) are a group of acquired hematopoietic stem cell disorders that manifest with progressive bone marrow failure and have a propensity to transform into leukemia. Although an increase in biologic understanding of MDS has led to improved patient risk stratification ...

Last Updated: 2 Jun 2016

Go To URL
Myelodysplastic syndromes: Contemporary review and how we treat.
 

Author(s): Naseema Gangat, Mrinal M Patnaik, Ayalew Tefferi

Journal: Am. J. Hematol.. 2016 Jan;91(1):76-89.

 

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal stem cell disorders with an inherent tendency for leukemic transformation. Diagnosis is currently based on the presence of peripheral blood cytopenias, peripheral blood and bone marrow dysplasia/blasts, and clonal ...

Last Updated: 15 Jan 2016

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Study of DSP-7888 in Patients With Myelodysplastic Syndrome
 

Status: Recruiting

Condition Summary: Myelodysplastic Syndrome

 

Last Updated: 15 Jan 2017

Go to URL
Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome
 

Status: Recruiting

Condition Summary: Myelodysplastic Syndrome

 

Last Updated: 22 Nov 2016

Go to URL